

Received: 2005.03.10
Accepted: 2005.04.28
Published: 2005.12.15

Neutrophils in the innate immune response

Scott D. Kobayashi*, Jovanka M. Voyich*, Christopher Burlak* and Frank R. DeLeo

Laboratory of Human Bacterial Pathogenesis, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA

Source of support: by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases.

Summary

Polymorphonuclear leukocytes (PMNs or neutrophils) are an essential component of the human innate immune system. Circulating neutrophils are rapidly recruited to sites of infection by host- and/or pathogen-derived components, which also prime these host cells for enhanced microbicidal activity. PMNs bind and ingest microorganisms by a process known as phagocytosis, which typically triggers production of reactive oxygen species and the fusion of cytoplasmic granules with pathogen-containing vacuoles. The combination of neutrophil reactive oxygen species and granule components is highly effective in killing most bacteria and fungi. Inasmuch as PMNs are the most abundant type of leukocyte in humans and contain an arsenal of cytotoxic compounds that are non-specific, neutrophil homeostasis must be highly regulated. To that end, constitutive PMN turnover is regulated by apoptosis, a process whereby these cells shut down and are removed safely by macrophages. Notably, apoptosis is accelerated following phagocytosis of bacteria, a process that appears important for the resolution of infection and inflammation. This review provides a general overview of the role of human neutrophils in the innate host response to infection and summarizes some of the recent advances in neutrophil biology.

Key words: neutrophil • phagocytosis • inflammation • infection • apoptosis

* Authors contributed equally.

Full-text PDF: http://www.aite-online/pdf/vol_53/no_6/8424.pdf

Author's address: Frank R. DeLeo, Ph.D., Laboratory of Human Bacterial Pathogenesis, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA, tel.: +1 406 363-9448, fax: +1 406 363-9394, e-mail: fdeleo@niaid.nih.gov

GRANULOPOIESIS

Cells of the immune system are derived from pluripotent stem cells in bone marrow^{14, 15, 41}. At an early stage in granulopoiesis, these hematopoietic stem cells give rise to unipotent myeloblasts (committed stem cells)⁹⁶, which differentiate subsequently into granulocytes (reviewed by Cline³⁴). Based on *in vivo* radiolabeling studies in humans^{40, 146, 198}, differentiation from myeloblasts to myelocytes normally requires ~7.5 days and from myelocytes to mature polymorphonuclear leukocytes (PMNs, neutrophils, or granulocytes) ~6.5 days (summarized by Bainton et al.⁷). From these studies it is estimated that granulocyte precursors comprise ~60% of the nucleated cells in bone marrow⁷. Myeloblasts lack granules ultimately present in mature PMNs, but have numerous ribosomes and mitochondria⁷. Azurophilic and specific granules are formed during the promyelocyte and myelocyte stages of differentiation, respectively⁷. As myeloid precursors become mature neutrophils, they sequentially acquire the receptors and proteins needed for innate host defense (reviewed by Faurschou and Borregaard⁵⁹). Mature PMNs are released into the bloodstream where they circulate with a typical half-life of 6–8 h^{6, 34, 40, 62}. Although PMNs have a relatively short life-span, the greatest percentage of hematopoiesis is committed to the production of neutrophils, and PMN turnover is on the order of 10¹¹ cells per day in the average adult human⁶.

NEUTROPHIL RECRUITMENT AND PHAGOCYTOSIS

Recruitment

Active recruitment of neutrophils to sites of infection is fundamentally important to the innate immune system. This multi-step process involves mobilization of PMNs from circulation and bone marrow reserves in response to host- and pathogen-derived chemotactic factors. Neutrophils roll along the walls of postcapillary venules, surveying connective tissue, mucosal membranes, skeletal muscle, and lymphatic organs for signs of tissue distress and the presence of chemoattractants¹⁰⁹. There are numerous host-derived factors that trigger recruitment of neutrophils. One of the most potent neutrophil chemoattractants is the chemokine interleukin (IL)-8^{196, 211}. IL-8 is produced by many cell types during inflammatory states such as that accompanying infection. These cells include monocytes, macrophages, mast cells, epithelial cells, keratinocytes, fibroblasts, endothelial cells, and neutrophils (discussed below). Bacteria also produce molecules that directly recruit PMNs (e.g. *N*-formylated peptides)^{170, 177}. An impor-

tant property of chemoattractants is that they can prime neutrophils for enhanced function, thereby facilitating host defense.

Priming

Neutrophil “priming” was described by McPhail et al.¹³³ in the early 1980s as the ability of a primary agonist, typically at a sub-stimulatory concentration, to influence/enhance superoxide production triggered by a second stimulus. Since that time, many studies have shown that neutrophils can be primed for enhanced adhesion, phagocytosis, production of reactive oxygen species (ROS), cytokine secretion, leukotriene synthesis, degranulation, and bactericidal activity (see Table 1 for a comprehensive list of priming agents). Many neutrophil priming agents are host derived and include cytokines, chemokines, growth factors, and lipid-derived signaling molecules (Table 1). Cell-cell contact²¹⁵ and adherence/adhesion^{71, 88, 123} also prime cells for enhanced function (Table 1). As implied above, microorganisms produce numerous factors that prime PMNs for enhanced responses to subsequent stimuli^{50, 53, 54, 63, 74, 119, 124, 133, 205} (Table 1). Many priming agents are Toll-like receptor (TLR) agonists, and TLRs are thus critical components in the pathogen-mediated priming process (see below). A distinction can be made between primed cells and those that are fully activated¹³³. Priming typically includes mobilization of secretory vesicles and secretion of cytokines, but fails to induce complete degranulation or elicit production of superoxide. Arguably, the single most important role for PMN priming is to promote efficient clearance of invading microorganisms.

Neutrophil rolling, tethering, and adhesion

PMN “rolling” in blood vessels is mediated by a family of C-type lectin glycoproteins known as selectins¹⁰⁹. Selectin levels are modulated on the surface of cytokine-activated endothelial cells (E- and P-selectin), activated platelets (P-selectin), and on primed or activated neutrophils (L-selectin)¹⁸⁴. For example, P-selectin is up-regulated on the surface of endothelial cells following exposure to leukotriene B₄, histamine, or complement peptide C5a⁶⁴. E- and P-selectins interact with neutrophil CD162 (P-selectin glycoprotein ligand-1) to facilitate a process known as “tethering”, which mediates rolling¹³⁷. Selectin-supported tethering precedes firm adhesion mediated by leukocyte adhesion molecules such as β1 (VLA-4)- and β2-integrins (Mac-1 or LFA-1)^{116, 194}. Once firmly bound, several neutrophil surface molecules, including CD31¹³⁹, CD54⁵¹, CD44⁹³, and CD47³⁸, facilitate transmigration through the endothelium into tissues.

Table 1. Molecules or processes that prime neutrophils

Priming agent or process	Priming function with 2 nd stimulus	Reference
fMLP (≤ 300 nM)	enhanced O_2^- production	133
PMA (≤ 160 nM)	enhanced O_2^- production	133, 186
A23187 (≤ 1 μ M)	enhanced O_2^- production	133
Ionomycin	enhanced O_2^- production	60
DAG	enhanced O_2^- production	10, 13
PAF	enhanced O_2^- production, actin polymerization, elastase release	175, 189
GM-CSF	enhanced O_2^- production, chemotaxis, phagocytosis, degranulation, leukotriene synthesis, arachidonate release, DAG synthesis	8, 9, 43, 52, 187, 201
G-CSF	enhanced O_2^- production	8, 213
TNF- α	enhanced O_2^- production, phospholipase D activation, phospholipase A2 activation, direct surface receptor up-regulation	11, 12, 37, 94
IFN- γ	enhanced O_2^- production	183, 185
IFN- α	enhanced O_2^- and leukotriene B4 production	3
IL-1 α	enhanced O_2^- production	165
IL-1 β	enhanced O_2^- production, elastase release, phospholipase D activity, and calcium flux	18, 25
IL-2	enhanced O_2^- production	183
IL-3	enhanced O_2^- production, chemotaxis	30, 76
IL-5	enhanced chemotaxis	76
IL-6	enhanced O_2^- production	95
IL-8	enhanced O_2^- production, phospholipase A2 activation, secretory vesicle mobilization	46, 134, 157, 206, 212
IL-15	enhanced O_2^- production	140
IL-18	enhanced O_2^- production and cytokine secretion	87, 209
GRO α	enhanced O_2^- production	134
Insulin-like growth factor I	enhanced phagocytosis, degranulation	20
Methionine-enkephalin, β -endorphin	enhanced O_2^- production, secretory vesicle mobilization	75, 145
Thrombopoietin	enhanced O_2^- production	26
Thrombospondin	enhanced chemotaxis	127
Human growth hormone	enhanced O_2^- production and adhesion	203
Fibronectin	enhanced O_2^- production	180
Tachykinins (substance P)	enhanced O_2^- production	28
C2-ceramide	enhanced O_2^- production	156
Diamide (thiol oxidizer)	enhanced O_2^- production	138
N-acetyl-S-(3-oxo-3-carboxy-n-propyl)cysteine	enhanced O_2^- production	86
Pooled human albumin	enhanced O_2^- production, elastase release	152
Bovine milk	enhanced O_2^- production	182
Lysophosphatidylcholine	enhanced degranulation	178
Peroxyxynitrite	enhanced O_2^- production, secretory vesicle mobilization	159
ROS (hydrogen peroxide)	enhanced FcR phagocytosis	148
Ischemia/reperfusion	enhanced O_2^- production	89
Adherence	elevation of cytosolic free calcium	71, 88, 123
Extended hypotonic conditions	enhanced O_2^- production	84
Cell-cell contact	enhanced O_2^- production	215
Cross-linking of CD18	enhanced O_2^- production	118
Moderate exercise	enhanced O_2^- production	179
β -glucan via CR3 binding	enhanced cytotoxicity	191
Brain natriuretic peptide	enhanced O_2^- production	70
Cigarette smoke condensate	enhanced O_2^- production, elastase release	105
Sulfur mustard (2,2'-bis-chloroethyl sulfide)	enhanced O_2^- production	115
Temperature	enhanced O_2^- production	90
LPS	enhanced O_2^- production, degranulation, PAF release, leukotriene release, enhanced release of arachidonic acid, secretory vesicle mobilization	50, 53, 54, 63, 74, 205
LTA	enhanced O_2^- production, degranulation	124
Staphylococcal PSM	enhanced O_2^- production	119
Muramyl peptide molecules	enhanced O_2^- production	91
Sulfolipid I from <i>Mycobacterium tuberculosis</i>	enhanced O_2^- production	216
Neisserial porins	enhanced O_2^- production	21
Mycobacterial lipoarabinomannans	enhanced O_2^- production, secretory vesicle mobilization	58
Epstein-Barr virus	enhanced leukotriene B4 production	72
Influenza virus	enhanced O_2^- production	29
Attenuated poxviruses	enhanced O_2^- production	65
Newcastle disease virus neuraminidase	enhanced O_2^- production	5

fMLP – N-formylated peptides, PMA – phorbol myristate acetate, DAG – diacylglycerol, PAF – platelet activating factor, GM-CSF – granulocyte-macrophage colony-stimulating factor, G-CSF – granulocyte colony-stimulating factor, IFN – interferon, ROS – reactive oxygen species, LPS – lipopolysaccharide, LTA – lipoteichoic acid, PSM – phenol-soluble modulin.

Phagocytosis

At the site of infection, neutrophils bind and ingest invading microorganisms by a process known as phagocytosis. PMNs directly recognize surface-bound or freely secreted molecules produced by bacteria, including peptidoglycan, lipoproteins, lipoteichoic acid, lipopolysaccharide (LPS), CpG-containing DNA, and flagellin. These pathogen-derived molecules, known as pathogen-associated molecular patterns, interact directly with a number of pattern-recognition receptors expressed on the cell surface, including TLRs (reviewed by Akira and Takeda²) and CD14^{200, 207, 208}. Recent studies by Hayashi et al.⁷⁸ demonstrated that TLRs 1, 2, and 4–10 are expressed in/on human neutrophils, extending earlier findings¹⁴¹. Ligation of neutrophil TLRs, especially TLRs 2 and 4, activates signal transduction pathways that ultimately prolong cell survival¹⁶⁴, facilitate adhesion¹⁶⁴ and phagocytosis⁷⁸, enhance release of cytokines, chemokines, and ROS^{78, 108, 164}, and promote degranulation^{17, 124}, thereby contributing to microbicidal activity¹⁷. Peptidoglycan-recognition protein (PGRP) is another recently described pattern-recognition molecule that plays a role in the intracellular killing of Gram-positive bacteria by neutrophils^{55, 92, 120, 121}. There are four known isoforms of PGRP in mammals, and neutrophils express PGRP-short (PGRP-S, also known as PGLYRP1), a protein that binds peptidoglycan and Gram-positive bacteria^{55, 121}. PGRP-S contributes directly to bactericidal activity rather than promoting pathogen recognition and uptake¹²⁰. Neutrophil phagocytosis is also facilitated by several other host pattern-recognition molecules known as the collectins, which are reviewed elsewhere¹²⁵.

Although pattern-recognition receptors play a role in the recognition of microbes by neutrophils, the effi-

ciency of phagocytosis by neutrophils is markedly enhanced if microbes are opsonized with serum host proteins, such as complement and/or antibody. Activation of complement promotes the deposition of complement components C3b, iC3b, and C1q on microbial surfaces¹⁴⁴. Complement-opsonized microbes are efficiently recognized by complement surface receptors on PMNs, including C1qR⁵⁶, CD35 (CR1)^{153, 163}, CD11b/CD18 (CR3)^{45, 81}, and CD11c/CD18 (CR4)¹⁴² (reviewed by Nauseef and Clark¹⁴⁴). Antibody-coated microbes are recognized by neutrophil receptors specific for the Fc-region of antibody, such as CD23 (FcεRI, IgE receptor)⁷³, CD89 (FcαR, IgA receptor)⁴, CD64 (FcγRI, IgG receptor), CD32 (FcγRIIa, low-affinity IgG receptor)^{129, 144}, and CD16 (FcγRIIIb, low-affinity IgG receptor)^{61, 129}. Binding of antibody and complement receptors at the PMN surface triggers phagocytosis of microorganisms (Fig. 1).

Production of cytokines and chemokines by activated neutrophils

Recent studies have shown that phagocytosis of bacteria triggers synthesis of neutrophil genes encoding many immunomodulatory agents, including IL-1α, IL-1β, IL-1ε, IL-1RN, IL-6, IL-8, IL-10, IL-12β, IL-15, IL-18, CCL2 (MIP1α), CCL3 (MIP1β), CXCL1 (GROα), CXCL2 (MIP2α), CXCL3 (MIP2β), CXCL12 (SDF1), CCL20 (MIP3α), tumor necrosis factor (TNF)-α, vascular endothelial cell growth factor, and oncostatin M^{23, 102, 103, 169}. In addition to recruiting more PMNs and modulating subsequent neutrophil functions, these molecules potentially coordinate early responses of monocytes, macrophages, dendritic cells, and lymphocytes during inflammatory states. Importantly, production of cytokines and chemokines by PMNs serves as a first




Figure 1. Neutrophil phagocytosis and activation of microbicidal systems. Microbes opsonized with serum complement components (complement) and specific antibody (antibody) are efficiently bound by complement receptors (CRs) and antibody Fc receptors (FcRs) on the surface of neutrophils. Ligation of these receptors drives the process of phagocytosis whereby microorganisms are internalized and sequestered within a phagosome. Degranulation and production of superoxide by an NADPH-dependent oxidase promote efficient killing of ingested microbes. See text for details. MPO – myeloperoxidase, HOCl – hypochlorous acid, e – electron, 2° ROS – secondarily derived reactive oxygen species.

link between the innate and acquired immune responses. This topic is reviewed in detail by Scapini et al.¹⁶⁹.

Immune evasion strategies employed by bacteria

Although most bacteria are recognized and destroyed by PMNs, some pathogenic bacteria have developed clever strategies to inhibit PMN recruitment and phagocytosis. *Streptococcus pyogenes* is a human pathogen that employs several novel mechanisms to circumvent destruction by neutrophils (reviewed by Voyich et al.¹⁹⁵). For example, *S. pyogenes* produces a 130-kDa serine endopeptidase aptly called C5a peptidase that specifically cleaves the complement chemoattractant C5a to inhibit PMN recruitment³³. In addition, strains of *S. pyogenes* that cause necrotizing fasciitis or “flesh-eating” infections release a trypsin-like protease that degrades IL-8⁸². Reduced levels of IL-8 may contribute to the observed paucity of neutrophils at the site of *S. pyogenes* soft-tissue infections⁸². The pathogen disrupts other critical aspects of PMN function including deposition of opsonins and phagocytosis¹⁹⁵. For example, the surface M protein of *S. pyogenes* impedes the binding of opsonic fragment C3b to its surface by inhibiting complement regulatory proteins, such as C4b-binding protein, factor H, and factor H-like protein¹⁹. *S. pyogenes* also secretes Mac, a host-receptor mimetic of the leukocyte β 2-integrin Mac-1, which interacts with CD16 and Mac-1 at the neutrophil plasma membrane to inhibit opsonophagocytosis¹¹². Streptococcal inhibitor of complement is a protein secreted by *S. pyogenes* that blocks PMN phagocytosis by presumably altering normal PMN cytoskeleton function⁸⁵. Although the molecules involved in these mechanisms of immune evasion are specific to *S. pyogenes*, the general strategies, i.e. inhibition of phagocytosis and chemotaxis, are commonly used by other bacterial pathogens.

NEUTROPHIL MICROBICIDAL ACTIVITY

Human neutrophils use oxygen-dependent and oxygen-independent mechanisms to kill ingested microorganisms. Phagocytosis of microorganisms triggers generation of superoxide radicals and other secondarily derived ROS, such as hydrogen peroxide, hypochlorous acid, hydroxyl radical, and chloramines¹³¹, which are potent microbicidal agents¹⁰⁰. Concomitant with the production of ROS, cytoplasmic granules fuse with bacteria-containing phagosomes (a process known as degranulation), thereby enriching the vacuole lumen with antimicrobial peptides and proteases (Fig. 1).

NADPH oxidase and the production of superoxide

In activated neutrophils, a membrane-bound NADPH-dependent oxidase generates high levels of superoxide, a process traditionally called “respiratory burst” (reviewed by Quinn and Gauss¹⁴⁹) (Fig. 1). In unstimulated neutrophils, components of the NADPH oxidase complex are separated in cytosol (p40*phox*, p47*phox*, p67*phox*, Rac2)^{114, 122, 192, 193, 204} and membrane compartments (flavocytochrome *b*₅₅₈, Rap1A)^{24, 150, 172}. During phagocytosis, the cytosolic components translocate to the plasma and/or phagosome membrane and associate with flavocytochrome *b*₅₅₈, a transmembrane heterodimer comprised of gp91*phox* (Nox2) and p22*phox*, thereby forming the active oxidase^{32, 49, 80, 192}. The oxidase transfers electrons from cytosolic NADPH to intraphagosomal molecular oxygen, thus producing superoxide. Superoxide anion is short-lived and dismutates rapidly to hydrogen peroxide and forms other secondary products, such as hypochlorous acid, hydroxyl radical, and singlet oxygen, which are effective microbicidal compounds^{98, 99, 160, 161}. The importance of NADPH oxidase and the production of ROS is exemplified by a rare hereditary disorder known as chronic granulomatous disease (CGD; for recent reviews see refs.^{113, 162}). Individuals with CGD have recurrent bacterial and fungal infections due to defects in the NADPH oxidase^{113, 162}. These infections are often life threatening, although advances in the therapeutic interventions for CGD, such as treatment with interferon- γ or itraconazole, have significantly improved prognosis^{66, 130}.

Myeloperoxidase-halide system

Early studies by Klebanoff and coworkers demonstrated that the microbicidal activity of NADPH oxidase-derived ROS is augmented significantly by myeloperoxidase (MPO), an abundant hemoprotein stored within neutrophil azurophilic granules^{98–100, 160, 161, 171}. During cell activation, MPO is targeted to forming phagosomes and catalyzes a reaction with chloride and hydrogen peroxide to produce hypochlorous acid, a potent microbicidal agent^{98–100} (Fig. 1). This reaction comprises what is known as the MPO-halide system¹⁰⁰. Curiously, individuals with hereditary deficiency of MPO typically lack increased susceptibility to infection¹⁴³, and it has been proposed that superoxide and hydrogen peroxide, and granule components, may be sufficient to compensate for the lack of the MPO-halide system and its products under certain conditions^{100, 143, 144}. Despite overwhelming evidence, which indicates ROS and neutrophil granules are independently microbicidal^{98–100, 143, 160, 161}, recent work by Segal and coworkers sug-

gests ROS may have limited capacity for direct microbicidal activity^{1, 154}. Further work is necessary to elucidate the basis for these provocative observations.

Degranulation

Neutrophil phagocytosis triggers mobilization of cytoplasmic granules, which fuse either with the plasma membrane (exocytosis) or with phagosomes⁸³ (Fig. 1). The regulatory mechanisms underlying granule mobilization and targeting following activation are incompletely defined, but involve in part calcium- and/or ceramide-mediated signal transduction, Src family tyrosine kinases FGR and HCK, p38 MAP kinase, and soluble *N*-ethylmaleimide sensitive factor attaching proteins (SNAPs) and SNAP receptors^{27, 128, 132, 135, 136, 174}. Importantly, fusion of azurophilic granules with phagosomes enriches the vacuole lumen with numerous anti-microbial peptides, including α -defensins, cathepsins, proteinase-3, elastase, azurocidin, and lysozyme⁵⁹. Neutrophil α -defensins, known as HNP 1–4 (reviewed by Ganz⁶⁸ and Lehrer¹¹⁰), comprise up to 50% of the protein in azurophilic granules¹⁵⁵ and have potent antimicrobial activity^{42, 69, 111, 117, 173}. Defensins are relatively small cationic polypeptides of 3–5 kDa that interact with negatively charged molecules at the pathogen surface and permeabilize bacterial membranes⁶⁸. PMN α -defensins modulate a number of other functions in innate host defense, including chemotaxis, wound repair, and histamine release¹¹⁰, and are clearly important mediators of human innate host defense. Degranulation also enriches phagosomes with components of the specific granules, such as flavocytochrome *b*₅₅₈²⁴ and lactoferrin¹⁹⁷, further augmenting anti-microbial potential⁹⁷. Lactoferrin sequesters iron needed for growth of many microorganisms and, conversely, supplies iron required to generate neutrophil hydroxyl radical¹⁰¹. Notably, lactoferrin has direct microbicidal activity against bacteria that involves membrane permeabilization¹⁶.

Bystander tissue damage and disorders linked to neutrophil-mediated inflammation processes

Although the cytotoxic components produced by neutrophils kill ingested microorganisms efficiently, host tissues can be damaged inadvertently by PMNs through the action of degradative enzymes and the production of ROS. Cell activation and granule exocytosis, prolonged acute inflammatory responses, tissue remodeling, and PMN lysis at the site of infection can each contribute to inflammatory disorders. For example, rheumatoid arthritis has been linked to the production of ROS by neutrophils following activa-

tion by immune complexes in the synovial fluid of joints. Oxidation of low-density lipoproteins (LDLs) by superoxide and neutrophil-derived ROS likely contributes to atherosclerosis^{47, 79, 106, 126, 181}. These oxidized LDLs are recognized by resident macrophages, thereby facilitating processes that lead to atherosclerosis^{47, 79, 106, 151}. This idea is supported by the finding that neutrophils activated by hypochlorous acid-oxidized LDL adhere to epithelial cells and subsequently activate to produce ROS^{106, 126, 181}. Host tissue damage caused by some types of *Staphylococcus aureus* pneumonia (necrotizing pneumonia) is presumably due to neutrophil lysis, although the hypothesis remains to be tested directly. Thus it is critical that neutrophil homeostasis and turnover are highly regulated processes during infection and inflammation.

NEUTROPHIL APOPTOSIS AND THE RESOLUTION OF INFECTION

Overview of the importance of neutrophil apoptosis

Apoptosis is an important mechanism for maintaining homeostasis of the human immune system. For example, apoptosis plays a critical role in shaping both T and B cell repertoires by deleting unproductive as well as potentially autoreactive immune cells³¹. In addition, programmed cell death plays a major role in the normal turnover of cells of the innate immune system³⁵. Although the process of apoptosis is ubiquitous in immune cells, there is considerable difference in the rate of turnover of various cell types and the impact on resolution of inflammation (reviewed in refs.^{35, 48}). Since neutrophils are the most numerous type of leukocyte in humans, with rapid turnover and an abundance of potent cytotoxic components, there is potential for tissue injury and trauma associated with inflammatory disease (see above). Hence the importance of appropriate neutrophil apoptosis is underscored by inflammatory potential and possible host tissue damage should they undergo lysis.

Normal turnover of aging neutrophils occurs in the absence of activation through a process known as spontaneous apoptosis¹⁶⁶. The intrinsic ability of neutrophils to undergo apoptosis is essential for maintaining appropriate cell numbers in circulation¹⁷⁶. Notably, the process of neutrophil apoptosis is significantly accelerated upon activation by phagocytosis^{39, 67, 104}. Together, these processes limit inappropriate inflammatory potential and are critical to the resolution of infection. It is therefore conceivable that bacterial pathogens have evolved mechanisms to exploit this essential cellular process to promote pathogenesis.

Apoptosis as a critical component of the resolution phase of inflammation and infection

The onset of human bacterial disease is accompanied by the active recruitment of massive numbers of neutrophils to infected tissues. PMNs remove bacteria via phagocytosis, and initiation of the neutrophil-mediated acute-phase inflammatory response is crucial for the resolution of infection. On the other hand, the timely removal of activated PMNs from affected sites is paramount to the resolution of inflammation. Thus, the resolution phase of both inflammation and infection requires a delicate balance between both neutrophil survival and death signals.

Bacterial infections are accompanied by important host responses, including release of proinflammatory cytokines, which alter neutrophil apoptosis. In general, cytokines such as TNF- α , IL-1 β , IL-6, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor delay spontaneous PMN apoptosis³⁶. In addition, bacteria-derived products such as LPS and a number of bacterial toxins are known to delay neutrophil apoptosis⁴⁸. Together, these observations suggest that enhanced neutrophil survival is a desirable consequence during early stages of inflammation and promotes the clearance of bacterial pathogens. It is increasingly clear that the process of phagocytosis significantly accelerates the rate of apoptosis in human PMNs^{39, 67, 102, 199, 214}. Consistent with this idea, neutrophil ingestion of *Escherichia coli*, *Neisseria gonorrhoeae*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Staphylococcus aureus*, *Mycobacterium tuberculosis*, *Burkholderia cepacia*, *Borrelia hermsii*, and *Listeria monocytogenes* significantly accelerates the rate of PMN apoptosis⁴⁸. Importantly, phagocytosis significantly increases the rate of PMN apoptosis irrespective of any delay in cell fate imparted by cytokines or bacteria-derived factors^{57, 199}. Neutrophil apoptosis is also associated with an overall decrease in cellular function. For example, apoptotic neutrophils have diminished capability to chemotax, produce ROS, secrete cytokines, adhere, and phagocytose^{103, 202}. In addition, proinflammatory capacity is down-regulated during neutrophil apoptosis¹⁰³. As a critical step toward resolution of inflammation, PMNs undergo cell surface changes that include the external expression of components such as phosphatidylserine^{77, 167, 168}. Apoptotic neutrophils are subsequently recognized and ingested by either macrophages or neighboring cells in the absence of proinflammatory consequence¹⁶⁸. Thus, PMN apoptosis plays a central role in the resolution of infection and the control of inflammation.

Altering apoptosis as a mechanism of pathogenesis

The ability of neutrophils to undergo apoptosis is essential for the maintenance of human health. Thus it is not surprising that bacterial pathogens are capable of exploiting this critical process in order to survive and cause disease. However, the relatively short life-span of neutrophils is not conducive to long-term survival of most intracellular pathogens. In order for intracellular pathogens to replicate and persist in PMNs, the ability of these pathogens to alter neutrophil apoptosis would facilitate their survival in these short-lived granulocytes. Although several bacterial pathogens have been reported to survive in PMNs, only two have been shown conclusively to delay neutrophil apoptosis. *Anaplasma phagocytophilum*, the causative agent of human granulocytic anaplasmosis, was the first described bacterial pathogen to both replicate and delay PMN apoptosis²¹⁰. Although not sharing the same tropism for granulocytes as *A. phagocytophilum*, the obligate intracellular bacterial pathogen *Chlamydia pneumoniae* has recently been shown to multiply in neutrophils and delay spontaneous apoptosis¹⁸⁸. Thus, intracellular bacterial pathogens are able to extend neutrophil life-span by altering normal apoptosis²³. The specific cellular mechanisms responsible for pathogen-mediated inhibition of neutrophil apoptosis are unclear, and further research on this topic will likely reveal insight into bacterial pathogenesis.

As described in the previous section, accelerated neutrophil apoptosis after phagocytosis of bacteria is a normal and desirable phenomenon that contributes to the resolution of infection. However, recent evidence suggests that bacterial pathogens such as *S. pyogenes* can additionally alter neutrophil apoptosis in a manner that ultimately results in rapid cell lysis¹⁰². In the absence of a normal progression of apoptosis in activated neutrophils, the inability of macrophages to safely remove PMNs prior to lysis would presumably lead to unfettered inflammation at infection sites. These findings are consistent with the clinical presentation of necrotic lesions and gross inflammation often associated with *S. pyogenes* infections¹⁰⁷. Thus, the ability of pathogens to alter neutrophil fate by either blocking apoptosis to facilitate intracellular pathogen survival or promoting rapid lysis to eliminate neutrophils represents plausible mechanisms of virulence. However, the complex association of neutrophils, macrophages, and secreted pathogen and host factors at infection sites complicate this rather simplistic model. Appropriate *in vitro* and *in vivo* model systems will prove invaluable for providing specific molecular mechanisms for the role of neutrophil apoptosis in bacterial pathogenesis.

CONCLUSIONS

Neutrophils form the first and most prominent line of cellular defense against invading microorganisms. The importance of neutrophils in the immune system is exemplified by patients with neutropenia or defects that impair neutrophil function. Such individuals are predisposed to serious infections that are typically life threatening^{22, 44, 113, 147, 158, 162, 190}. The processes of PMN recruitment, transmigration, phagocytosis, and activation are highly coordinated to prevent or eliminate human infections. Although most bacteria are killed by neutrophils in healthy individuals, there are a number of human pathogens that circumvent PMN function and thereby cause disease. For some pathogens, survival in the human host is accom-

plished by inhibiting neutrophil phagocytosis, altering cell activation (i.e. ROS production and degranulation), causing host cell lysis, modulating apoptosis, or a combination of these mechanisms. Recent studies have provided insight into mechanisms used by pathogens to circumvent killing by PMNs. An enhanced understanding of these mechanisms as well as a better understanding of neutrophil function will ultimately result in new prophylactic agents or therapeutics designed to prevent and control infections.

ACKNOWLEDGMENT

The authors thank Mark T. Quinn (Montana State University, Bozeman, MT, USA) for critical review of the manuscript.

REFERENCES

- Ahluwalia J., Tinker A., Clapp L. H., Duchon M. R., Abramov A. Y., Pope S., Nobles M. and Segal A. W. (2004): The large-conductance Ca^{2+} -activated K^{+} channel is essential for innate immunity. *Nature*, 427, 853–858.
- Akira S. and Takeda K. (2004): Toll-like receptor signalling. *Nat. Rev. Immunol.*, 4, 499–511.
- Al-Shabanah O. A., Mansour M. A. and Elmazar M. M. (1999): Enhanced generation of leukotriene B₄ and superoxide radical from calcium ionophore (A23187) stimulated human neutrophils after priming with interferon- α . *Res. Commun. Mol. Pathol. Pharmacol.*, 106, 115–128.
- Albrechtsen M., Yeaman G. R. and Kerr M. A. (1988): Characterization of the IgA receptor from human polymorphonuclear leucocytes. *Immunology*, 64, 201–205.
- Almkvist J., Dahlgren C., Leffler H. and Karlsson A. (2004): Newcastle disease virus neuraminidase primes neutrophils for stimulation by galectin-3 and formyl-Met-Leu-Phe. *Exp. Cell Res.*, 298, 74–82.
- Athens J. W., Haab O. P., Raab S. O., Mauer A. M., Ashenbrucker H., Cartwright G. E. and Wintrobe M. M. (1961): Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. *J. Clin. Invest.*, 40, 989–995.
- Bainton D. F., Ulliyot J. L. and Farquhar M. G. (1971): The development of neutrophilic polymorphonuclear leukocytes in human bone marrow. *J. Exp. Med.*, 134, 907–934.
- Balazovich K. J., Almeida H. I. and Boxer L. A. (1991): Recombinant human G-CSF and GM-CSF prime human neutrophils for superoxide production through different signal transduction mechanisms. *J. Lab. Clin. Med.*, 118, 576–584.
- Baldwin G. C., Fuller N. D., Roberts R. L., Ho D. D. and Golde D. W. (1989): Granulocyte- and granulocyte-macrophage colony-stimulating factors enhance neutrophil cytotoxicity toward HIV-infected cells. *Blood*, 74, 1673–1677.
- Bass D. A., Gerard C., Olbrantz P., Wilson J., McCall C. E. and McPhail L. C. (1987): Priming of the respiratory burst of neutrophils by diacylglycerol. Independence from activation or translocation of protein kinase C. *J. Biol. Chem.*, 262, 6643–6649.
- Bauldry S. A., Bass D. A., Cousart S. L. and McCall C. E. (1991): Tumor necrosis factor α priming of phospholipase D in human neutrophils. Correlation between phosphatidic acid production and superoxide generation. *J. Biol. Chem.*, 266, 4173–4179.
- Bauldry S. A., McCall C. E., Cousart S. L. and Bass D. A. (1991): Tumor necrosis factor- α priming of phospholipase A₂ activation in human neutrophils. An alternative mechanism of priming. *J. Immunol.*, 146, 1277–1285.
- Bauldry S. A., Wykle R. L. and Bass D. A. (1988): Phospholipase A₂ activation in human neutrophils. Differential actions of diacylglycerols and alkylacylglycerols in priming cells for stimulation by N-formyl-Met-Leu-Phe. *J. Biol. Chem.*, 263, 16787–16795.
- Baum C. M., Weissman I. L., Tsukamoto A. S., Buckle A. M. and Peault B. (1992): Isolation of a candidate human hematopoietic stem-cell population. *Proc. Natl. Acad. Sci. USA*, 89, 2804–2808.
- Becker A. J., McCulloch E. A. and Till J. E. (1963): Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. *Nature*, 197, 452–454.
- Bellamy W., Takase M., Yamauchi K., Wakabayashi H., Kawase K. and Tomita M. (1992): Identification of the bactericidal domain of lactoferrin. *Biochim. Biophys. Acta*, 1121, 130–136.
- Bellocchio S., Moretti S., Perruccio K., Fallarino F., Bozza S., Montagnoli C., Mosci P., Lipford G. B., Pitzurra L. and Romani L. (2004): TLRs govern neutrophil activity in aspergillosis. *J. Immunol.*, 173, 7406–7415.
- Bergensfeldt M., Linder C. and Ohlsson K. (1992): Stimulation of human polymorphonuclear leukocytes by recombinant human interleukin-1 β . *Biol. Chem. Hoppe Seyler*, 373, 255–260.
- Bisno A. L., Brito M. O. and Collins C. M. (2003): Molecular basis of group A streptococcal virulence. *Lancet Infect. Dis.*, 3, 191–200.
- Bjerknes R. and Aarskog D. (1995): Priming of human polymorphonuclear neutrophilic leukocytes by insulin-like growth factor I: Increased phagocytic capacity, complement receptor expression, degranulation, and oxidative burst. *J. Clin. Endocrinol. Metab.*, 80, 1948–1955.
- Bjerknes R., Guttormsen H. K., Solberg C. O. and Wetzler L. M. (1995): Neisserial porins inhibit human neutrophil actin polymerization, degranulation, opsonin receptor expression, and phagocytosis but prime the neutrophils to increase their oxidative burst. *Infect. Immun.*, 63, 160–167.
- Bodey G. P., Buckley M., Sathe Y. S. and Freireich E. J. (1966): Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Ann. Intern. Med.*, 64, 328–340.
- Borjesson D. L., Kobayashi S. D., Whitney A. R., Voyich J. M., Argue C. M. and DeLeo F. R. (2005): Insights into pathogen immune evasion mechanisms: *Anaplasma phagocytophilum* fails to induce an apoptosis differentiation program in human neutrophils. *J. Immunol.*, 174, 6364–6372.
- Borreagaard N., Heiple J. M., Simons E. R. and Clark R. A. (1983): Subcellular localization of the b-cytochrome component of the human neutrophil microbicidal oxidase: Translocation during activation. *J. Cell. Biol.*, 97, 52–61.

25. Brandolini L., Bertini R., Bizzarri C., Sergi R., Caselli G., Zhou D., Locati M. and Sozzani S. (1996): IL-1 beta primes IL-8-activated human neutrophils for elastase release, phospholipase D activity, and calcium flux. *J. Leukoc. Biol.*, 59, 427–434.
26. Brizzi M. F., Battaglia E., Rosso A., Strippoli P., Montrucchio G., Camussi G. and Pegoraro L. (1997): Regulation of polymorphonuclear cell activation by thrombopoietin. *J. Clin. Invest.*, 99, 1576–1584.
27. Brumell J. H., Volchuk A., Sengelov H., Borregaard N., Cieutat A. M., Bainton D. F., Grinstein S. and Klip A. (1995): Subcellular distribution of docking/fusion proteins in neutrophils, secretory cells with multiple exocytic compartments. *J. Immunol.*, 155, 5750–5759.
28. Brunelleschi S., Tarli S., Giotti A. and Fantozzi R. (1991): Priming effects of mammalian tachykinins on human neutrophils. *Life Sci.*, 48, L1–L5.
29. Busse W. W., Vrtis R. F., Steiner R. and Dick E. C. (1991): In vitro incubation with influenza virus primes human polymorphonuclear leukocyte generation of superoxide. *Am. J. Respir. Cell Mol. Biol.*, 4, 347–354.
30. Carlson M., Peterson C. and Venge P. (1993): The influence of IL-3, IL-5, and GM-CSF on normal human eosinophil and neutrophil C3b-induced degranulation. *Allergy*, 48, 437–442.
31. Chan K. F., Siegel M. R. and Lenardo J. M. (2000): Signaling by the TNF receptor superfamily and T cell homeostasis. *Immunity*, 13, 419–422.
32. Clark R. A., Volpp B. D., Leidal K. G. and Nauseef W. M. (1990): Two cytosolic components of the human neutrophil respiratory burst oxidase translocate to the plasma membrane during cell activation. *J. Clin. Invest.*, 85, 714–721.
33. Cleary P. P., Prahbu U., Dale J. B., Wexler D. E. and Handley J. (1992): Streptococcal C5a peptidase is a highly specific endopeptidase. *Infect. Immun.*, 60, 5219–5223.
34. Cline M. J. (1975): Production, destruction, and distribution of neutrophilic granulocytes. In Cline M. J.: *The White Cell*. Harvard University Press, Cambridge, 24–38.
35. Cohen J. J., Duke R. C., Fadok V. A. and Sellins K. S. (1992): Apoptosis and programmed cell death in immunity. *Annu. Rev. Immunol.*, 10, 267–293.
36. Colotta F., Re F., Polentarutti N., Sozzani S. and Mantovani A. (1992): Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. *Blood*, 80, 2012–2020.
37. Condliffe A. M., Chilvers E. R., Haslett C. and Dransfield I. (1996): Priming differentially regulates neutrophil adhesion molecule expression/function. *Immunology*, 89, 105–111.
38. Cooper D., Lindberg F. P., Gamble J. R., Brown E. J. and Vadas M. A. (1995): Transendothelial migration of neutrophils involves integrin-associated protein (CD47). *Proc. Natl. Acad. Sci. USA*, 92, 3978–3982.
39. Coxon A., Rieu P., Barkalow F. J., Askari S., Sharpe A. H., von Adrian U. H., Arnaout M. A. and Mayadas T. N. (1996): A novel role for the $\beta 2$ integrin CD11b/CD18 in neutrophil apoptosis: A homeostatic mechanism in inflammation. *Immunity*, 5, 653–666.
40. Cronkite E. P. and Flidner T. M. (1964): Granulocytopoiesis. *N. Engl. J. Med.*, 270, 1347–1352.
41. Cudkovic G., Bennett M. and Shearer G. M. (1964): Pluripotent stem cell function of the mouse marrow “lymphocyte”. *Science*, 144, 866–868.
42. Daher K. A., Selsted M. E. and Lehrer R. I. (1986): Direct inactivation of viruses by human granulocyte defensins. *J. Virol.*, 60, 1068–1074.
43. Dahinden C. A., Zingg J., Maly F. E. and de Weck A. L. (1988): Leukotriene production in human neutrophils primed by recombinant human granulocyte/macrophage colony-stimulating factor and stimulated with the complement component C5A and FMLP as second signals. *J. Exp. Med.*, 167, 1281–1295.
44. Dale D. C., Guerry D., Wewerka J. R., Bull J. M. and Chusid M. J. (1979): Chronic neutropenia. *Medicine (Baltimore)*, 58, 128–144.
45. Dana N., Todd R. F. III, Pitt J., Springer T. A. and Arnaout M. A. (1984): Deficiency of a surface membrane glycoprotein (Mo1) in man. *J. Clin. Invest.*, 73, 153–159.
46. Daniels R. H., Finnen M. J., Hill M. E. and Lackie J. M. (1992): Recombinant human monocyte IL-8 primes NADPH-oxidase and phospholipase A2 activation in human neutrophils. *Immunology*, 75, 157–163.
47. Daugherty A., Dunn J. L., Rateri D. L. and Heinecke J. W. (1994): Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. *J. Clin. Invest.*, 94, 437–444.
48. DeLeo F. R. (2004): Modulation of phagocyte apoptosis by bacterial pathogens. *Apoptosis*, 9, 399–413.
49. DeLeo F. R., Allen L. A., Apicella M. and Nauseef W. M. (1999): NADPH oxidase activation and assembly during phagocytosis. *J. Immunol.*, 163, 6732–6740.
50. DeLeo F. R., Renee J., McCormick S., Nakamura M., Apicella M., Weiss J. P. and Nauseef W. M. (1998): Neutrophils exposed to bacterial lipopolysaccharide upregulate NADPH oxidase assembly. *J. Clin. Invest.*, 101, 455–463.
51. Diamond M. S., Staunton D. E., de Fougerolles A. R., Stacker S. A., Garcia-Aguilar J., Hibbs M. L. and Springer T. A. (1990): ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). *J. Cell Biol.*, 111, 3129–3139.
52. DiPersio J. F., Billing P., Williams R. and Gasson J. C. (1988): Human granulocyte-macrophage colony-stimulating factor and other cytokines prime human neutrophils for enhanced arachidonic acid release and leukotriene B4 synthesis. *J. Immunol.*, 140, 4315–4322.
53. Doerfler M. E., Danner R. L., Shelhamer J. H. and Parrillo J. E. (1989): Bacterial lipopolysaccharides prime human neutrophils for enhanced production of leukotriene B4. *J. Clin. Invest.*, 83, 970–977.
54. Doerfler M. E., Weiss J., Clark J. D. and Elsbach P. (1994): Bacterial lipopolysaccharide primes human neutrophils for enhanced release of arachidonic acid and causes phosphorylation of an 85-kD cytosolic phospholipase A2. *J. Clin. Invest.*, 93, 1583–1591.
55. Dziarski R., Platt K. A., Gelius E., Steiner H. and Gupta D. (2003): Defect in neutrophil killing and increased susceptibility to infection with nonpathogenic gram-positive bacteria in peptidoglycan recognition protein-S (PGRP-S)-deficient mice. *Blood*, 102, 689–697.
56. Eggleton P., Ghebrehiwet B., Sastry K. N., Coburn J. P., Zaner K. S., Reid K. B. and Tauber A. I. (1995): Identification of a gC1q-binding protein (gC1q-R) on the surface of human neutrophils. Subcellular localization and binding properties in comparison with the cC1q-R. *J. Clin. Invest.*, 95, 1569–1578.
57. Engelich G., White M. and Hartshorn K. L. (2001): Neutrophil survival is markedly reduced by incubation with influenza virus and *Streptococcus pneumoniae*: role of respiratory burst. *J. Leukoc. Biol.*, 69, 50–56.
58. Faldt J., Dahlgren C., Ridell M. and Karlsson A. (2001): Priming of human neutrophils by mycobacterial lipoarabinomannans: role of granule mobilisation. *Microbes Infect.*, 3, 1101–1109.
59. Faurschou M. and Borregaard N. (2003): Neutrophil granules and secretory vesicles in inflammation. *Microbes Infect.*, 5, 1317–1327.
60. Finkel T. H., Pabst M. J., Suzuki H., Guthrie L. A., Forehand J. R., Phillips W. A. and Johnston R. B., Jr. (1987): Priming of neutrophils and macrophages for enhanced release of superoxide anion by the calcium ionophore ionomycin. Implications for regulation of the respiratory burst. *J. Biol. Chem.*, 262, 12589–12596.
61. Fleit H. B., Wright S. D. and Unkeless J. C. (1982): Human neutrophil Fc gamma receptor distribution and structure. *Proc. Natl. Acad. Sci. USA*, 79, 3275–3279.
62. Flidner T. M., Cronkite E. P. and Robertson J. S. (1964): Granulocytopoiesis. I. Senescence and random loss of neutrophilic granulocytes in human beings. *Blood*, 24, 402–414.
63. Forehand J. R., Pabst M. J., Phillips W. A. and Johnston R. B. Jr. (1989): Lipopolysaccharide priming of human neutrophils for an enhanced respiratory burst: role of intracellular free calcium. *J. Clin. Invest.*, 83, 74–83.

64. Foreman K. E., Vaporciyan A. A., Bonish B. K., Jones M. L., Johnson K. J., Glovsky M. M., Eddy S. M. and Ward P. A. (1994): C5a-induced expression of P-selectin in endothelial cells. *J. Clin. Invest.*, 94, 1147–1155.
65. Forster R., Wolf G. and Mayr A. (1994): Highly attenuated poxviruses induce functional priming of neutrophils *in vitro*. *Arch. Virol.*, 136, 219–226.
66. Gallin J. I., Alling D. W., Malech H. L., Wesley R., Koziol D., Marciano B., Eisenstein E. M., Turner M. L., DeCarlo E. S., Starling J. M. and Holland S. M. (2003): Itraconazole to prevent fungal infections in chronic granulomatous disease. *N. Engl. J. Med.*, 348, 2416–2422.
67. Gamberale R., Giordano M., Trevani A. S., Andonegui G. and Geffner J. R. (1998): Modulation of human neutrophil apoptosis by immune complexes. *J. Immunol.*, 161, 3666–3674.
68. Ganz T. (2001): Defensins in the urinary tract and other tissues. *J. Infect. Dis.*, 183 (suppl. 1), S41–S42.
69. Ganz T., Selsted M. E., Szklarek D., Harwig S. S., Daher K., Bainton D. F. and Lehrer R. I. (1985): Defensins. Natural peptide antibiotics of human neutrophils. *J. Clin. Invest.*, 76, 1427–1435.
70. Garlachs C. D., Zhang H., Schmeisser A. and Daniel W. G. (1999): Priming of superoxide anion in polymorphonuclear neutrophils by brain natriuretic peptide. *Life Sci.*, 65, 1027–1033.
71. Ginis I., Zaner K., Wang J. S., Pavlotsky N. and Tauber A. I. (1992): Comparison of actin changes and calcium metabolism in plastic- and fibronectin-adherent human neutrophils. *J. Immunol.*, 149, 1388–1394.
72. Gosselin J., Savard M., Tardif M., Flamand L. and Borgeat P. (2001): Epstein-Barr virus primes human polymorphonuclear leukocytes for the biosynthesis of leukotriene B₄. *Clin. Exp. Immunol.*, 126, 494–502.
73. Gounni A. S., Lamkhouiou B., Koussih L., Ra C., Renzi P. M. and Hamid Q. (2001): Human neutrophils express the high-affinity receptor for immunoglobulin E (Fc epsilon RI): role in asthma. *FASEB J.*, 15, 940–949.
74. Guthrie L. A., McPhail L. C., Henson P. M. and Johnston R. B. Jr. (1984): Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide. Evidence for increased activity of the superoxide-producing enzyme. *J. Exp. Med.*, 160, 1656–1671.
75. Haberstock H. and Marotti T. (1997): Methionine-enkephalin primes human neutrophils for enhanced superoxide anion production. *Immunopharmacol. Immunotoxicol.*, 19, 135–145.
76. Hakansson L. and Venge P. (1994): Priming of eosinophil and neutrophil migratory responses by interleukin 3 and interleukin 5. *APMIS*, 102, 308–316.
77. Hart S. P., Ross J. A., Ross K., Haslett C. and Dransfield I. (2000): Molecular characterization of the surface of apoptotic neutrophils: Implications for functional downregulation and recognition by phagocytes. *Cell Death Differ.*, 7, 493–503.
78. Hayashi F., Means T. K. and Luster A. D. (2003): Toll-like receptors stimulate human neutrophil function. *Blood*, 102, 2660–2669.
79. Hazell L. J., Arnold L., Flowers D., Waeg G., Malle E. and Stocker R. (1996): Presence of hypochlorite-modified proteins in human atherosclerotic lesions. *J. Clin. Invest.*, 97, 1535–1544.
80. Heyworth P. G., Bohl B. P., Bokoch G. M. and Curnutte J. T. (1994): Rac translocates independently of the neutrophil NADPH oxidase components p47phox and p67phox. Evidence for its interaction with flavocytochrome b558. *J. Biol. Chem.*, 269, 30749–30752.
81. Hickstein D. D., Ozols J., Williams S. A., Baenziger J. U., Locksley R. M. and Roth G. J. (1987): Isolation and characterization of the receptor on human neutrophils that mediates cellular adherence. *J. Biol. Chem.*, 262, 5576–5580.
82. Hidalgo-Grass C., Dan-Goor M., Maly A., Eran Y., Kwinn L. A., Nizet V., Ravins M., Jaffe J., Peyser A., Moses A. E. and Hanski E. (2004): Effect of a bacterial pheromone peptide on host chemokine degradation in group A streptococcal necrotizing soft-tissue infections. *Lancet*, 363, 696–703.
83. Hirsch J. G. and Cohn Z. A. (1960): Degranulation of polymorphonuclear leucocytes following phagocytosis of microorganisms. *J. Exp. Med.*, 112, 1005–1014.
84. Hiura M., Ozawa M., Ohtsuka T., Takesue H., Yamaguchi M., Okamura N. and Ishibashi S. (1991): Stimulation of superoxide anion production in guinea pig polymorphonuclear leukocytes by hypotonic conditions in combination with protein kinase C activators. *Arch. Biochem. Biophys.*, 291, 31–37.
85. Hoe N. P., Ireland R. M., DeLeo F. R., Gowen B. B., Dorward D. W., Voyich J. M., Liu M., Burns E. H. Jr., Culnan D. M., Bretscher A. and Musser J. M. (2002): Insight into the molecular basis of pathogen abundance: group A *Streptococcus* inhibitor of complement inhibits bacterial adherence and internalization into human cells. *Proc. Natl. Acad. Sci. USA*, 99, 7646–7651.
86. Ito O., Zhang J. Y., Zhang M. Y., Sagara Y., Masuoka N., Ubuka T. and Kodama H. (1997): Priming effect of N-acetyl-S-(3-oxo-3-carboxy-n-propyl)cysteine in human neutrophils and tyrosyl phosphorylation of 45 kDa protein. *Clin. Chim. Acta*, 266, 93–104.
87. Jablonska E., Izycka A., Jablonska J., Wawrusiewicz N. and Piecuch J. (2001): Role of IL-18 in the secretion of IL-1beta, sIL-1RII, and IL-1Ra by human neutrophils. *Immunol. Invest.*, 30, 221–229.
88. Jaconi M. E., Theler J. M., Schlegel W., Appel R. D., Wright S. D. and Lew P. D. (1991): Multiple elevations of cytosolic-free Ca²⁺ in human neutrophils: initiation by adherence receptors of the integrin family. *J. Cell Biol.*, 112, 1249–1257.
89. Jaeschke H., Bautista A. P., Spolarics Z. and Spitzer J. J. (1991): Superoxide generation by Kupffer cells and priming of neutrophils during reperfusion after hepatic ischemia. *Free Radic. Res. Commun.*, 15, 277–284.
90. Jozefowicz-Okonkwo G. and Nowak D. (2004): Temperature can prime human peripheral blood neutrophils in a p38MAPKalpha-dependent manner. *Arch. Immunol. Ther. Exp.*, 52, 447–456.
91. Jupin C., Parant M., Chedid L. and Damais C. (1987): Enhanced oxidative burst without interleukin 1 production by normal human polymorphonuclear leukocytes primed with muramyl dipeptides. *Inflammation*, 11, 153–161.
92. Kang D., Liu G., Lundstrom A., Gelius E. and Steiner H. (1998): A peptidoglycan recognition protein in innate immunity conserved from insects to humans. *Proc. Natl. Acad. Sci. USA*, 95, 10078–10082.
93. Khan A. I., Kerfoot S. M., Heit B., Liu L., Andonegui G., Ruffell B., Johnson P. and Kubes P. (2004): Role of CD44 and hyaluronan in neutrophil recruitment. *J. Immunol.*, 173, 7594–7601.
94. Kharazmi A., Nielsen H. and Bendtzen K. (1988): Modulation of human neutrophil and monocyte chemotaxis and superoxide responses by recombinant TNF-alpha and GM-CSF. *Immunobiology*, 177, 363–370.
95. Kharazmi A., Nielsen H., Rechnitzer C. and Bendtzen K. (1989): Interleukin 6 primes human neutrophil and monocyte oxidative burst response. *Immunol. Lett.*, 21, 177–184.
96. Killmann S. A., Cronkite E. P., Flidner T. M. and BOND V. P. (1962): Mitotic indices of human bone marrow cells. I. Number and cytologic distribution of mitoses. *Blood*, 19, 743–750.
97. Kjeldsen L., Sengelov H., Lollike K., Nielsen M. H. and Borregaard N. (1994): Isolation and characterization of gelatinase granules from human neutrophils. *Blood*, 83, 1640–1649.
98. Klebanoff S. J. (1968): Myeloperoxidase-halide-hydrogen peroxide antibacterial system. *J. Bacteriol.*, 95, 2131–2138.
99. Klebanoff S. J. (1974): Role of the superoxide anion in the myeloperoxidase-mediated antimicrobial system. *J. Biol. Chem.*, 249, 3724–3728.
100. Klebanoff S. J. (2005): Myeloperoxidase: friend and foe. *J. Leukoc. Biol.*, 77, 598–625.
101. Klebanoff S. J. and Waltersdorff A. M. (1990): Prooxidant activity of transferrin and lactoferrin. *J. Exp. Med.*, 172, 1293–1303.
102. Kobayashi S. D., Braughton K. R., Whitney A. R., Voyich J. M., Schwan T. G., Musser J. M. and DeLeo F. R. (2003): Bacterial pathogens modulate an apoptosis differentiation program in human neutrophils. *Proc. Natl. Acad. Sci. USA*, 100, 10948–10953.

103. Kobayashi S. D., Voyich J. M., Braughton K. R. and DeLeo F. R. (2003): Down-regulation of proinflammatory capacity during apoptosis in human polymorphonuclear leukocytes. *J. Immunol.*, 170, 3357–3368.
104. Kobayashi S. D., Voyich J. M., Buhl C. L., Stahl R. M. and DeLeo F. R. (2002): Global changes in gene expression by human polymorphonuclear leukocytes during receptor-mediated phagocytosis: Cell fate is regulated at the level of gene expression. *Proc. Natl. Acad. Sci. USA*, 99, 6901–6906.
105. Koethe S. M., Kuhnmuensch J. R. and Becker C. G. (2000): Neutrophil priming by cigarette smoke condensate and a tobacco anti-idiotypic antibody. *Am. J. Pathol.*, 157, 1735–1743.
106. Koppasch S., Leonhardt W., Pietzsch J. and Kuhne H. (1998): Hypochlorite-modified low-density lipoprotein stimulates human polymorphonuclear leukocytes for enhanced production of reactive oxygen metabolites, enzyme secretion, and adhesion to endothelial cells. *Atherosclerosis*, 136, 315–324.
107. Krause R. M. (2002): Evolving microbes and re-emerging streptococcal disease. *Clin. Lab Med.*, 22, 835–848.
108. Kurt-Jones E. A., Mandell L., Whitney C., Padgett A., Gosselin K., Newburger P. E. and Finberg R. W. (2002): Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. *Blood*, 100, 1860–1868.
109. Lawrence M. B. and Springer T. A. (1991): Leukocytes roll on a selectin at physiologic flow rates - distinction from and prerequisite for adhesion through integrins. *Cell*, 65, 859–873.
110. Lehrer R. I. (2004): Primate defensins. *Nat. Rev. Microbiol.*, 2, 727–738.
111. Lehrer R. I., Szklarek D., Ganz T. and Selsted M. E. (1986): Synergistic activity of rabbit granulocyte peptides against *Candida albicans*. *Infect. Immun.*, 52, 902–904.
112. Lei B., DeLeo F. R., Hoe N. P., Graham M. R., Mackie S. M., Cole R. L., Liu M., Hill H. R., Low D. E., Federle M. J., Scott J. R. and Musser J. M. (2001): Evasion of human innate and acquired immunity by a bacterial homolog of CD11b that inhibits opsonophagocytosis. *Nat. Med.*, 7, 1298–1305.
113. Leksstrom-Himes J. A. and Gallin J. I. (2000): Immunodeficiency diseases caused by defects in phagocytes. *N. Engl. J. Med.*, 343, 1703–1714.
114. Leto T. L., Lomax K. J., Volpp B. D., Nunoi H., Sechler J. M. G., Nauseef W. M., Clark R. A., Gallin J. I. and Malech H. L. (1990): Cloning of a 67-kD neutrophil oxidase factor with similarity to a noncatalytic region of p60-src. *Science*, 248, 727–730.
115. Levitt J. M., Lodhi I. J., Nguyen P. K., Ngo V., Clift R., Hinshaw D. B. and Sweeney J. F. (2003): Low-dose sulfur mustard primes oxidative function and induces apoptosis in human polymorphonuclear leukocytes. *Int. Immunopharmacol.*, 3, 747–756.
116. Ley K. (2002): Integration of inflammatory signals by rolling neutrophils. *Immunol. Rev.*, 186, 8–18.
117. Lichtenstein A., Ganz T., Selsted M. E. and Lehrer R. I. (1986): *In vitro* tumor cell cytotoxicity mediated by peptide defensins of human and rabbit granulocytes. *Blood*, 68, 1407–1410.
118. Liles W. C., Ledbetter J. A., Waltersdorff A. W. and Klebanoff S. J. (1995): Cross-linking of CD18 primes human neutrophils for activation of the respiratory burst in response to specific stimuli: Implications for adhesion-dependent physiological responses in neutrophils. *J. Leukoc. Biol.*, 58, 690–697.
119. Liles W. C., Thomsen A. R., O'Mahony D. S. and Klebanoff S. J. (2001): Stimulation of human neutrophils and monocytes by staphylococcal phenol-soluble modulin. *J. Leukoc. Biol.*, 70, 96–102.
120. Liu C., Gelius E., Liu G., Steiner H. and Dziarski R. (2000): Mammalian peptidoglycan recognition protein binds peptidoglycan with high affinity, is expressed in neutrophils, and inhibits bacterial growth. *J. Biol. Chem.*, 275, 24490–24499.
121. Liu C., Xu Z., Gupta D. and Dziarski R. (2001): Peptidoglycan recognition proteins: a novel family of four human innate immunity pattern recognition molecules. *J. Biol. Chem.*, 276, 34686–34694.
122. Lomax K. J., Leto T. L., Nunoi H., Gallin J. I. and Malech H. L. (1989): Recombinant 47-kilodalton cytosolic factor restores NADPH oxidase in chronic granulomatous disease. *Science*, 245, 409–412.
123. Lorant D. E., Topham M. K., Whatley R. E., McEver R. P., McIntyre T. M., Prescott S. M. and Zimmerman G. A. (1993): Inflammatory roles of P-selectin. *J. Clin. Invest.*, 92, 559–570.
124. Lotz S., Aga E., Wilde I., van Z. G., Hartung T., Solbach W. and Laskay T. (2004): Highly purified lipoteichoic acid activates neutrophil granulocytes and delays their spontaneous apoptosis via CD14 and TLR2. *J. Leukoc. Biol.*, 75, 467–477.
125. Lu J., Teh C., Kishore U. and Reid K. B. (2002): Collectins and ficolins: sugar pattern recognition molecules of the mammalian innate immune system. *Biochim. Biophys. Acta*, 1572, 387–400.
126. Ludwig P. W., Hunninghake D. B. and Hoidal J. R. (1982): Increased leucocyte oxidative metabolism in hyperlipoproteinaemia. *Lancet*, 2, 348–350.
127. Mansfield P. J., Boxer L. A. and Suchard S. J. (1990): Thrombospondin stimulates motility of human neutrophils. *J. Cell Biol.*, 111, 3077–3086.
128. Mansfield P. J., Hinkovska-Galcheva V., Carey S. S., Shayman J. A. and Boxer L. A. (2002): Regulation of polymorphonuclear leukocyte degranulation and oxidant production by ceramide through inhibition of phospholipase D. *Blood*, 99, 1434–1441.
129. Mantovani B. (1975): Different roles of IgG and complement receptors in phagocytosis by polymorphonuclear leukocytes. *J. Immunol.*, 115, 15–17.
130. Marciano B. E., Wesley R., De Carlo E. S., Anderson V. L., Barnhart L. A., Darnell D., Malech H. L., Gallin J. I. and Holland S. M. (2004): Long-term interferon-gamma therapy for patients with chronic granulomatous disease. *Clin. Infect. Dis.*, 39, 692–699.
131. Marcinkiewicz J. (1997): Neutrophil chloramines: missing links between innate and acquired immunity. *Immunol. Today*, 18, 577–580.
132. Martin-Martin B., Nabokina S. M., Blasi J., Lazo P. A. and Mollinedo F. (2000): Involvement of SNAP-23 and syntaxin 6 in human neutrophil exocytosis. *Blood*, 96, 2574–2583.
133. McPhail L. C., Clayton C. C. and Snyderman R. (1984): The NADPH oxidase of human polymorphonuclear leukocytes. Evidence for regulation by multiple signals. *J. Biol. Chem.*, 259, 5768–5775.
134. Metzner B., Barbisch M., Parlow F., Kownatzki E., Schraufstatter I. and Norgauer J. (1995): Interleukin-8 and GRO alpha prime human neutrophils for superoxide anion production and induce up-regulation of N-formyl peptide receptors. *J. Invest. Dermatol.*, 104, 789–791.
135. Mócsai A., Jakus Z., Vántus T., Berton G., Lowell C. A. and Ligeti E. (2000): Kinase pathways in chemoattractant-induced degranulation of neutrophils: The role of p38 mitogen-activated protein kinase activated by Src family kinases. *J. Immunol.*, 164, 4321–4331.
136. Mócsai A., Ligeti E., Lowell C. A. and Berton G. (1999): Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck. *J. Immunol.*, 162, 1120–1126.
137. Moore K. L., Patel K. D., Bruehl R. E., Li F., Johnson D. A., Lichtenstein H. S., Cummings R. D., Bainton D. F. and McEver R. P. (1995): P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. *J. Cell Biol.*, 128, 661–671.
138. Moriguchi T., Seres T., Ravichandran V., Sasada M. and Johnston R. B. Jr. (1996): Diamide primes neutrophils for enhanced release of superoxide anion: relationship to S-thiolation of cellular proteins. *J. Leukoc. Biol.*, 60, 191–198.
139. Muller W. A., Weigl S. A., Deng X. and Phillips D. M. (1993): PECAM-1 is required for transendothelial migration of leukocytes. *J. Exp. Med.*, 178, 449–460.
140. Musso T., Calosso L., Zucca M., Millesimo M., Puliti M., Bulfone-Paus S., Merlino C., Savoia D., Cavallo R., Ponzi A. N. and Badolato R. (1998): Interleukin-15 activates proinflammatory and antimicrobial functions in polymorphonuclear cells. *Infect. Immun.*, 66, 2640–2647.

141. Muzio M., Bosio D., Polentarutti N., D'Amico G., Stoppacciaro A., Mancinelli R., van't Veer C., Penton-Rol G., Ruco L. P., Allavena P. and Mantovani A. (2000): Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. *J. Immunol.*, 164, 5998–6004.
142. Myones B. L., Dalzell J. G., Hogg N. and Ross G. D. (1988): Neutrophil and monocyte cell surface p150, 95 has iC3b-receptor (CR4) activity resembling CR3. *J. Clin. Invest.*, 82, 640–651.
143. Nauseef W. M. (1990): Myeloperoxidase deficiency. *Hematol. Pathol.*, 4, 165–178.
144. Nauseef W. M. and Clark R. A. (2000): Granulocytic phagocytes. In Mandell G. L., Bennett J. E. and Dolan R.: *Principles and Practice of Infectious Diseases*. Churchill Livingstone, New York-Edinburgh-London-Philadelphia, 5, 89–112.
145. Pasnik J., Tchorzewski H., Baj Z., Luciak M. and Tchorzewski M. (1999): Priming effect of met-enkephalin and β -endorphin on chemiluminescence, chemotaxis and CD11b molecule expression on human neutrophils *in vitro*. *Immunol. Lett.*, 67, 77–83.
146. Patt H. M. and Maloney M. A. (1964): A model of granulocyte kinetics. *Ann. NY Acad. Sci.*, 113, 513–522.
147. Pincus S. H., Boxer L. A. and Stossel T. P. (1976): Chronic neutropenia in childhood. Analysis of 16 cases and a review of the literature. *Am. J. Med.*, 61, 849–861.
148. Pricop L., Gokhale J., Redecha P., Ng S. C. and Salmon J. E. (1999): Reactive oxygen intermediates enhance Fc γ receptor signaling and amplify phagocytic capacity. *J. Immunol.*, 162, 7041–7048.
149. Quinn M. T. and Gauss K. A. (2004): Structure and regulation of the neutrophil respiratory burst oxidase: comparison with non-phagocyte oxidases. *J. Leukoc. Biol.*, 76, 760–781.
150. Quinn M. T., Parkos C. A., Walker L., Orkin S. H., Dinanier M. C. and Jesaitis A. J. (1989): Association of a ras-related protein with cytochrome b of human neutrophils. *Nature*, 342, 198–200.
151. Quinn M. T., Parthasarathy S., Fong L. G. and Steinberg D. (1987): Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. *Proc. Natl. Acad. Sci. USA*, 84, 2995–2998.
152. Rabaglia J. L., Gonzalez R., Moore E. E. and Harken A. H. (2002): Pooled human albumin primes neutrophils. *J. Cardiovasc. Surg.*, 17, 209–213.
153. Rabellino E. M., Ross G. D. and Polley M. J. (1978): Membrane receptors of mouse leukocytes. I. Two types of complement receptors for different regions of C3. *J. Immunol.*, 120, 879–885.
154. Reeves E. P., Lu H., Jacobs H. L., Messina C. G. M., Bolsover S., Gabella G., Potma E. O., Warley A., Roes J. and Segal A. W. (2002): Killing activity of neutrophils is mediated through activation of proteases by K⁺ flux. *Nature*, 416, 291–297.
155. Rice W. G., Ganz T., Kinkade J. M., Jr., Selsted M. E., Lehrer R. I. and Parmley R. T. (1987): Defensin-rich dense granules of human neutrophils. *Blood*, 70, 757–765.
156. Richard A., Bourgoin S., Naccache P. H., L'Heureux G. P., Krump E., McColl S. R. and Pelletier G. (1996): C2-ceramide primes specifically for the superoxide anion production induced by N-formylmethionylleucyl phenylalanine (fMLP) in human neutrophils. *Biochim. Biophys. Acta*, 1299, 259–266.
157. Roberts P. J., Pizzey A. R., Khwaja A., Carver J. E., Mire-Sluis A. R. and Linch D. C. (1993): The effects of interleukin-8 on neutrophil fMetLeuPhe receptors, CD11b expression and metabolic activity, in comparison and combination with other cytokines. *Br. J. Haematol.*, 84, 586–594.
158. Roberts S. R. and Kracke R. R. (1930): Agranulocytosis-report of a case. *JAMA*, 95, 780–787.
159. Rohn T. T., Nelson L. K., Sipes K. M., Swain S. D., Jutila K. L. and Quinn M. T. (1999): Priming of human neutrophils by peroxynitrite: potential role in enhancement of the local inflammatory response. *J. Leukoc. Biol.*, 65, 59–70.
160. Rosen H. and Klebanoff S. J. (1979): Bactericidal activity of a superoxide anion-generating system. A model for the polymorphonuclear leukocyte. *J. Exp. Med.*, 149, 27–39.
161. Rosen H. and Klebanoff S. J. (1977): Formation of singlet oxygen by the myeloperoxidase-mediated antimicrobial system. *J. Biol. Chem.*, 252, 4803–4810.
162. Rosenzweig S. D. and Holland S. M. (2004): Phagocyte immunodeficiencies and their infections. *J. Allergy Clin. Immunol.*, 113, 620–626.
163. Ross G. D., Jarowski C. I., Rabellino E. M. and Winchester R. J. (1978): The sequential appearance of Ia-like antigens and two different complement receptors during the maturation of human neutrophils. *J. Exp. Med.*, 147, 730–744.
164. Sabroe I., Prince L. R., Jones E. C., Horsburgh M. J., Foster S. J., Vogel S. N., Dower S. K. and Whyte M. K. (2003): Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span. *J. Immunol.*, 170, 5268–5275.
165. Sample A. K. and Czaprynski C. J. (1991): Priming and stimulation of bovine neutrophils by recombinant human interleukin-1 α and tumor necrosis factor α . *J. Leukoc. Biol.*, 49, 107–115.
166. Savill J. (1997): Apoptosis in resolution of inflammation. *J. Leukoc. Biol.*, 61, 375–380.
167. Savill J. S., Henson P. M. and Haslett C. (1989): Phagocytosis of aged human neutrophils by macrophages is mediated by a novel "charge-sensitive" recognition mechanism. *J. Clin. Invest.*, 84, 1518–1527.
168. Savill J. S., Wyllie A. H., Henson J. E., Walport M. J., Henson P. M. and Haslett C. (1989): Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. *J. Clin. Invest.*, 83, 865–875.
169. Scapini P., Lapinet-Vera J. A., Gasperini S., Calzetti F., Bazzoni F. and Cassatella M. A. (2000): The neutrophil as a cellular source of chemokines. *Immunol. Rev.*, 177, 195–203.
170. Schmeling D. J., Peterson P. K., Hammerschmidt D. E., Kim Y., Verhoef J., Wilkinson B. J. and Quie P. G. (1979): Chemotaxis by cell surface components of *Staphylococcus aureus*. *Infect. Immun.*, 26, 57–63.
171. Schultz J., Corlin R., Oddi F., Kaminker K. and Jones W. (1965): Myeloperoxidase of the leucocyte of normal human blood. 3. Isolation of the peroxidase granule. *Arch. Biochem. Biophys.*, 111, 73–79.
172. Segal A. W. and Jones O. T. G. (1978): Novel cytochrome b system in phagocytic vacuoles of human granulocytes. *Nature*, 276, 515–517.
173. Selsted M. E., Harwig S. S., Ganz T., Schilling J. W. and Lehrer R. I. (1985): Primary structures of three human neutrophil defensins. *J. Clin. Invest.*, 76, 1436–1439.
174. Sengelov H., Kjeldsen L. and Borregaard N. (1993): Control of exocytosis in early neutrophil activation. *J. Immunol.*, 150, 1535–1543.
175. Shalit M., Dabiri G. A. and Southwick F. S. (1987): Platelet-activating factor both stimulates and "primes" human polymorphonuclear leukocyte actin filament assembly. *Blood*, 70, 1921–1927.
176. Shi J., Gilbert G. E., Kokubo Y. and Ohashi T. (2001): Role of the liver in regulating numbers of circulating neutrophils. *Blood*, 98, 1226–1230.
177. Showell H. J., Freer R. J., Zigmond S. H., Shiffmann E., Aswanikumar S., Corcoran B. and Becker E. L. (1976): The structure-activity relations of synthetic peptides as chemotactic factors and inducers of lysosomal enzyme secretion for neutrophils. *J. Exp. Med.*, 143, 1154–1169.
178. Silliman C. C., Elzi D. J., Ambruso D. R., Musters R. J., Hamiel C., Harbeck R. J., Paterson A. J., Bjornsen A. J., Wyman T. H., Kelher M., England K. M., McLaughlin-Malaxeberria N., Barnett C. C., Aiboshi J. and Bannerjee A. (2003): Lysophosphatidylcholines prime the NADPH oxidase and stimulate multiple neutrophil functions through changes in cytosolic calcium. *J. Leukoc. Biol.*, 73, 511–524.
179. Smith J. A., Gray A. B., Pyne D. B., Baker M. S., Telford R. D. and Weidemann M. J. (1996): Moderate exercise triggers both priming and activation of neutrophil subpopulations. *Am. J. Physiol. Regul. Integr. Comp. Physiol.*, 270, R838–R845.

180. Stanislawski L., Huu T. P. and Perianin A. (1990): Priming effect of fibronectin on respiratory burst of human neutrophils induced by formyl peptides and platelet-activating factor. *Inflammation*, 14, 523–530.
181. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C. and Witztum J. L. (1989): Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. *N. Engl. J. Med.*, 320, 915–924.
182. Sugisawa H., Itou T., Ichimura Y. and Sakai T. (2002): Bovine milk enhances the oxidative burst activity of polymorphonuclear leukocytes in low concentrations. *J. Vet. Med. Sci.*, 64, 1113–1116.
183. Suzuki K., Furui H., Kaneko M., Takagi K. and Satake T. (1990): Priming effect of recombinant human interleukin-2 and recombinant human interferon-gamma on human neutrophil superoxide production. *Arzneimittelforschung*, 40, 1176–1179.
184. Tedder T. F., Penta A. C., Levine H. B. and Freedman A. S. (1990): Expression of the human leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens. *J. Immunol.*, 144, 532–540.
185. Tennenberg S. D., Fey D. E. and Lieser M. J. (1993): Oxidative priming of neutrophils by interferon- γ . *J. Leukoc. Biol.*, 53, 301–308.
186. Tyagi S. R., Tamura M., Burnham D. N. and Lambeth J. D. (1988): Phorbol myristate acetate (PMA) augments chemoattractant-induced diglyceride generation in human neutrophils but inhibits phosphoinositide hydrolysis. Implications for the mechanism of PMA priming of the respiratory burst. *J. Biol. Chem.*, 263, 13191–13198.
187. Tyagi S. R., Winton E. F. and Lambeth J. D. (1989): Granulocyte/macrophage colony-stimulating factor primes human neutrophils for increased diacylglycerol generation in response to chemoattractant. *FEBS Lett.*, 257, 188–190.
188. van Z. G., Gieffers J., Kothe H., Rupp J., Bollinger A., Aga E., Klinger M., Brade H., Dalhoff K., Maass M., Solbach W. and Laskay T. (2004): *Chlamydia pneumoniae* multiply in neutrophil granulocytes and delay their spontaneous apoptosis. *J. Immunol.*, 172, 1768–1776.
189. Vercellotti G. M., Yin H. Q., Gustafson K. S., Nelson R. D. and Jacob H. S. (1988): Platelet-activating factor primes neutrophil responses to agonists: role in promoting neutrophil-mediated endothelial damage. *Blood*, 71, 1100–1107.
190. Verdrengh M. and Tarkowski A. (1997): Role of neutrophils in experimental septicemia and septic arthritis induced by *Staphylococcus aureus*. *Infect. Immun.*, 65, 2517–2521.
191. Vetvicka V., Thornton B. P. and Ross G. D. (1996): Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. *J. Clin. Invest.*, 98, 50–61.
192. Volpp B. D., Nauseef W. M. and Clark R. A. (1988): Two cytosolic neutrophil oxidase components absent in autosomal chronic granulomatous disease. *Science*, 242, 1295–1297.
193. Volpp B. D., Nauseef W. M., Donelson J. E., Moser D. R. and Clark R. A. (1989): Cloning of the cDNA and functional expression of the 47-kilodalton cytosolic component of human neutrophil respiratory burst oxidase. *Proc. Natl. Acad. Sci. USA*, 86, 7195–7199.
194. von Andrian U. H., Chambers J. D., McEvoy L. M., Bargatze R. F., Arfors K. E. and Butcher E. C. (1991): Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte beta 2 integrins *in vivo*. *Proc. Natl. Acad. Sci. USA*, 88, 7538–7542.
195. Voyich J. M., Musser J. M. and DeLeo F. R. (2004): *Streptococcus pyogenes* and human neutrophils: a paradigm for evasion of innate host defense by bacterial pathogens. *Microbes Infect.*, 6, 1117–1123.
196. Walz A., Peveri P., Aschauer H. and Baggiolini M. (1987): Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. *Biochem. Biophys. Res. Commun.*, 149, 755–761.
197. Ward P. P. and Conneely O. M. (2004): Lactoferrin: role in iron homeostasis and host defense against microbial infection. *Biometals*, 17, 203–208.
198. Warner H. R. and Athens J. W. (1964): An analysis of granulocyte kinetics in blood and bone marrow. *Ann. NY Acad. Sci.*, 113, 523–536.
199. Watson R. W., Redmond H. P., Wang J. H. and Bouchier-Hayes D. (1996): Bacterial ingestion, tumor necrosis factor-alpha, and heat induce programmed cell death in activated neutrophils. *Shock*, 5, 47–51.
200. Weingarten R., Sklar L. A., Mathison J. C., Omid S., Ainsworth T., Simon S., Ulevitch R. J. and Tobias P. S. (1993): Interactions of lipopolysaccharide with neutrophils in blood via CD14. *J. Leukoc. Biol.*, 53, 518–524.
201. Weisbart R. H., Golde D. W. and Gasson J. C. (1986): Bio-synthetic human GM-CSF modulates the number and affinity of neutrophil f-Met-Leu-Phe receptors. *J. Immunol.*, 137, 3584–3587.
202. Whyte M. K., Meagher L. C., MacDermot J. and Haslett C. (1993): Impairment of function in aging neutrophils is associated with apoptosis. *J. Immunol.*, 150, 5124–5134.
203. Wiedermann C. J., Niedermühlbichler M., Geissler D., Beimpold H. and Braunsteiner H. (1991): Priming of normal human neutrophils by recombinant human growth hormone. *Br. J. Haematol.*, 78, 19–22.
204. Wientjes F. B., Hsuan J. J., Totty N. F. and Segal A. W. (1993): p40phox, a third cytosolic component of the activation complex of the NADPH oxidase to contain src homology 3 domains. *Biochem. J.*, 296, 557–561.
205. Worthen G. S., Seccombe J. F., Clay K. L., Guthrie L. A. and Johnston R. B. Jr. (1988): The priming of neutrophils by lipopolysaccharide for production of intracellular platelet-activating factor. Potential role in mediation of enhanced superoxide secretion. *J. Immunol.*, 140, 3553–3559.
206. Wozniak A., Betts W. H., Murphy G. A. and Rokicinski M. (1993): Interleukin-8 primes human neutrophils for enhanced superoxide anion production. *Immunology*, 79, 608–615.
207. Wright S. D., Ramos R. A., Hermanowski-Vosatka A., Rockwell P. and Detmers P. A. (1991): Activation of the adhesive capacity of CR3 on neutrophils by endotoxin: dependence on lipopolysaccharide binding protein and CD14. *J. Exp. Med.*, 173, 1281–1286.
208. Wright S. D., Ramos R. A., Tobias P. S., Ulevitch R. J. and Mathison J. C. (1990): CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. *Science*, 249, 1431–1433.
209. Wyman T. H., Dinarello C. A., Banerjee A., Gamboni-Robertson F., Hiester A. A., England K. M., Kelher M. and Silliman C. C. (2002): Physiological levels of interleukin-18 stimulate multiple neutrophil functions through p38 MAP kinase activation. *J. Leukoc. Biol.*, 72, 401–409.
210. Yoshiie K., Kim H. Y., Mott J. and Rikihisa Y. (2000): Intracellular infection by the human granulocytic ehrlichiosis agent inhibits human neutrophil apoptosis. *Infect. Immun.*, 68, 1125–1133.
211. Yoshimura T., Matsushima K., Tanaka S., Robinson E. A., Appella E., Oppenheim J. J. and Leonard E. J. (1987): Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. *Proc. Natl. Acad. Sci. USA*, 84, 9233–9237.
212. Yuo A., Kitagawa S., Kasahara T., Matsushima K., Saito M. and Takaku F. (1991): Stimulation and priming of human neutrophils by interleukin-8: cooperation with tumor necrosis factor and colony-stimulating factors. *Blood*, 78, 2708–2714.
213. Yuo A., Kitagawa S., Ohsaka A., Saito M. and Takaku F. (1990): Stimulation and priming of human neutrophils by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: qualitative and quantitative differences. *Biochem. Biophys. Res. Commun.*, 171, 491–497.
214. Zhang B., Hirahashi J., Cullere X. and Mayadas T. N. (2003): Elucidation of molecular events leading to neutrophil apoptosis following phagocytosis: cross-talk between caspase 8, reactive oxygen species, and MAPK/ERK activation. *J. Biol. Chem.*, 278, 28443–28454.
215. Zhang J. H., Ferrante A., Arrigo A. P. and Dayer J. M. (1992): Neutrophil stimulation and priming by direct contact with activated human T lymphocytes. *J. Immunol.*, 148, 177–181.
216. Zhang L., Goren M. B., Holzer T. J. and Andersen B. R. (1988): Effect of *Mycobacterium tuberculosis*-derived sulfolipid I on human phagocytic cells. *Infect. Immun.*, 56, 2876–2883.